ReviewCancers2024
Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- pH-responsive R848-loaded Cu MOF NPs potentiate anti-tumor immunity via synergistic photothermal therapy and immunotherapy in hepatocellular carcinoma.Materials today. Bio · 2026Article
- Targeting AATF reprograms the tumor microenvironment and suppresses hepatocellular carcinoma via MIR100HG-TGF-β signaling.Molecular therapy. Oncology · 2026Article
- Polyporusterone E, a Key Component ofInternational journal of molecular sciences · 2026Article
- Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era.Oncology and therapy · 2026Review
- Machine learning-based multi-omic analysis identifies CEP55, DLGAP5, and EZH2 as regulated cell death biomarkers linked to immunotherapy resistance in hepatocellular carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Personalized immunotherapy in HCC: synthesis, delivery, and clinical progress of mRNA-based vaccines.Cancer cell international · 2026Review
- Loss of SALL1 Promotes Hepatocellular Carcinoma Growth and Is Associated with Poor Clinical Outcome.Cancers · 2026Article
- MTARC1 p.A165 ablation reduces hepatocellular carcinoma aggressiveness in vitro and in vivo.Clinical and molecular hepatology · 2026Article
- Overexpression of NK4 suppresses hepatocellular carcinoma progression by inducing apoptosis and autophagy via MAPK pathway inhibition.Functional & integrative genomics · 2026Article
- Integrative bibliometrics and spatial transcriptomics identify CAF-associated genes and immune niches in hepatocellular carcinoma.Discover oncology · 2026Article
- Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances.Clinical and experimental medicine · 2026Review
- Signalling pathways in hepatocellular carcinoma (HCC) metastasis and invasion: Molecular mechanisms and therapeutic implications.Biochemistry and biophysics reports · 2026Review
- Xanthophyll-Rich Extracts fromNutrients · 2026Article
- Therapeutic Strategies for Hepatocellular Carcinoma: Current Advances and Future Perspectives.Vaccines · 2026Review
- Risk Scores for Stratifying Hepatocellular Carcinoma and Optimizing Surveillance Strategies.Cancers · 2026Review
- Role of insulin-like growth factor/receptor signaling in hepatocellular carcinoma.Hepatology forum · 2026Review
- Anlotinib plus penpulimab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the perspective of the Chinese healthcare system.Frontiers in oncology · 2026Article
- Current and Future Landscape of Hepatocellular Carcinoma Treatment.Oncology research · 2026Review
- Comparative efficacy of postoperative adjuvant transcatheter arterial chemoembolization versus lenvatinib plus tislelizumab in patients with BCLC stage 0 -B hepatocellular carcinoma after radical resection.Frontiers in immunology · 2026Article
- Inhibitory effects of patchouli alcohol on hepatocellular carcinoma growth through accumulation of oxidative stress and inactivation of androgen receptor signaling.International journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for ~90% of liver neoplasms. It is the second leading cause of cancer-related deaths and the seventh most common cancer worldwide. Although there have been rapid developments in the treatment of HCC over the past decade, the incidence and mortality rates of HCC remain a challenge. With the widespread use of the hepatitis B vaccine and antiviral therapy, the etiology of HCC is shifting more toward metabolic-associated steatohepatitis (MASH). Early-stage HCC can be treated with potentially curative strategies such as surgical resection, liver transplantation, and radiofrequency ablation, improving long-term survival. However, most HCC patients, when diagnosed, are already in the intermediate or advanced stages. Molecular targeted therapy, followed by immune checkpoint inhibitor immunotherapy, has been a revolution in HCC systemic treatment. Systemic treatment of HCC especially for patients with compromised liver function is still a challenge due to a significant resistance to immune checkpoint blockade, tumor heterogeneity, lack of oncogenic addiction, and lack of effective predictive and therapeutic biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.